Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with type 2 diabetes

Diabetic Medicine

Volumn 27, Issue 3, 2010, Pages 303-308

  Berthold, H K ^a   Bestehorn, K P ^b   Krone, W ^c   Gouni Berthold, I ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Atherosclerotic disease territory; Cardiovascular risk management; Diabetes; Hypertension; Lipid lowering

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC PATIENT; DISEASE DURATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SECONDARY PREVENTION; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; CROSS-SECTIONAL STUDY; HEALTH CARE DISPARITY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTHCARE DISPARITIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 77949408995     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02952.x     Document Type: Article

References (27)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31: S12-S54.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
4. Berthold H, Gouni-Berthold I, Bestehorn K, Böhm M, Krone W. Cardiovascular risk factors in patients with type 2 diabetes in Germany. Deutsches Ärzteblatt 2007; 104: A861-A867.
5. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care 2008; 31: 1389-1391.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. ADA Position Statement. Tenn Med 2000; 93: 419-429.
7. Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2008; 31: 69-74.
8. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46-51.
9. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
10. Kagan A, Gordon T, Rhoads G, Schiffman J. Some factors related to coronary heart disease incidence in Honolulu Japanese men. The Honolulu Heart Study. Int J Epidemiol 1975; 4: 271-279.
11. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990; 132: 1141-1155.
12. Smith SC Jr, Milani RV, Arnett DK, Crouse JR III, McDermott MM, Ridker PM et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004; 109: 2613-2616.
13. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109: 2617-2625.
14. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-899.
15. Pasternak RC, Criqui MH, Benjamin EJ, Fowkes FG, Isselbacher EM, McCullough PA et al. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. Circulation 2004; 109: 2605-2612.
16. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 2008; 117: 823-831.
17. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J Am Med Assoc 2001; 286: 1317-1324.
18. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg 2006; 44: 314-318.
19. McDermott MM, Hahn EA, Greenland P, Cella D, Ockene JK, Brogan D et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med 2002; 17: 895-904.
20. Collins R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
21. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007; Issue 4: CD000123.
22. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
23. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-463.
24. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
26. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
27. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.